Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

The bacterial effector protein YopM reduces rheumatoid arthritis (RA) outcome by inhibiting inflammation and bone destruction

Authors: J Bertrand, C Rueter, C Cromme, J Scharnert, A Schmidt, T Pap

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Osteoclasts mediate the degradation of bone during RA and are derived from macrophages. The yersinia outer protein M (YopM) is an effector protein of Yersinia species that is able to enter host cells by membrane penetration. In the cell YopM mediates down-regulation of inflammatory responses. We investigated whether YopM has the potential to act as a "selfdelivering" immune therapeutic agent by reducing the inflammation and joint destruction linked to RA. …
Metadata
Title
The bacterial effector protein YopM reduces rheumatoid arthritis (RA) outcome by inhibiting inflammation and bone destruction
Authors
J Bertrand
C Rueter
C Cromme
J Scharnert
A Schmidt
T Pap
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3609

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Poster presentation

Dendritic cell immunoreceptor (DCIR) is associated with anti-cyclic citrullinated peptides (anti-CCP) antibody - negative rheumatoid arthritis in Chinese Han population

Oral presentation

Synovial fibroblasts display an uncontrolled inflammatory and tissue destructive response to TNF-α

Poster presentation

An essential role of IκBζ in the transcriptional program in Th17 development

Poster presentation

Intermittent cold stress-induced experimental fibromyalgia model in mice - pharmacology and neurobiology

Oral presentation

Microparticles as antigenic targets in human and murine SLE

Poster presentation

Helicobacter pylori infection in rheumatic diseases
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits